Mesenchymal stem cells for cardiac regenerative therapy

K. H. Schuleri, A. J. Boyle, Joshua Hare

Research output: Chapter in Book/Report/Conference proceedingChapter

78 Citations (Scopus)

Abstract

Until recently, the concept of treating the injured or failing heart by generating new functional myocardium was considered physiologically impossible. Major scientific strides in the past few years have challenged the concept that the heart is a post-mitotic organ, leading to the hypothesis that cardiac regeneration could be therapeutically achieved. Bone marrow-derived adult stem cells were among the first cell populations that were used to test this hypothesis. Animal studies and early clinical experience support the concept that therapeutically delivered mesenchymal stem cells (MSCs) safely improve heart function after an acute myocardial infarction (MI). MSCs produce a variety of cardio-protective signalling molecules, and have the ability to differentiate into both myocyte and vascular lineages. Additionally, MSCs are attractive as a cellular vehicle for gene delivery, cell transplantation or for tissue engineering because they offer several practical advantages. They can be obtained in relatively large numbers through standard clinical procedures, and they are easily expanded in culture. The multi-lineage potential of MSC, in combination with their immunoprivileged status, make MSCs a promising source for cell therapy in cardiac diseases. Here we provide an overview of biological characteristics of MSCs, experimental animal studies and early clinical trials with MSCs. In addition, we discuss the routes of cell delivery, cell tracking experiments and current knowledge of the mechanistic underpinnings of their action.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
Pages195-218
Number of pages24
Volume180
DOIs
StatePublished - Dec 1 2007

Publication series

NameHandbook of Experimental Pharmacology
Volume180
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Therapeutics
Cell Tracking
Animals
Adult Stem Cells
Transplantation (surgical)
Cell Transplantation
Tissue Engineering
Cell- and Tissue-Based Therapy
Muscle Cells
Blood Vessels
Tissue engineering
Regeneration
Cell culture
Heart Diseases
Myocardium
Bone Marrow
Myocardial Infarction
Clinical Trials

Keywords

  • Acute myocardial infarction
  • Cell transplantation
  • Heart failure
  • Mesenchymal stem cells

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry
  • Medicine(all)

Cite this

Schuleri, K. H., Boyle, A. J., & Hare, J. (2007). Mesenchymal stem cells for cardiac regenerative therapy. In Handbook of Experimental Pharmacology (Vol. 180, pp. 195-218). (Handbook of Experimental Pharmacology; Vol. 180). https://doi.org/10.1007/978-3-540-68976-8-9

Mesenchymal stem cells for cardiac regenerative therapy. / Schuleri, K. H.; Boyle, A. J.; Hare, Joshua.

Handbook of Experimental Pharmacology. Vol. 180 2007. p. 195-218 (Handbook of Experimental Pharmacology; Vol. 180).

Research output: Chapter in Book/Report/Conference proceedingChapter

Schuleri, KH, Boyle, AJ & Hare, J 2007, Mesenchymal stem cells for cardiac regenerative therapy. in Handbook of Experimental Pharmacology. vol. 180, Handbook of Experimental Pharmacology, vol. 180, pp. 195-218. https://doi.org/10.1007/978-3-540-68976-8-9
Schuleri KH, Boyle AJ, Hare J. Mesenchymal stem cells for cardiac regenerative therapy. In Handbook of Experimental Pharmacology. Vol. 180. 2007. p. 195-218. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-540-68976-8-9
Schuleri, K. H. ; Boyle, A. J. ; Hare, Joshua. / Mesenchymal stem cells for cardiac regenerative therapy. Handbook of Experimental Pharmacology. Vol. 180 2007. pp. 195-218 (Handbook of Experimental Pharmacology).
@inbook{c910c3e62a1d44d7a87b495279586614,
title = "Mesenchymal stem cells for cardiac regenerative therapy",
abstract = "Until recently, the concept of treating the injured or failing heart by generating new functional myocardium was considered physiologically impossible. Major scientific strides in the past few years have challenged the concept that the heart is a post-mitotic organ, leading to the hypothesis that cardiac regeneration could be therapeutically achieved. Bone marrow-derived adult stem cells were among the first cell populations that were used to test this hypothesis. Animal studies and early clinical experience support the concept that therapeutically delivered mesenchymal stem cells (MSCs) safely improve heart function after an acute myocardial infarction (MI). MSCs produce a variety of cardio-protective signalling molecules, and have the ability to differentiate into both myocyte and vascular lineages. Additionally, MSCs are attractive as a cellular vehicle for gene delivery, cell transplantation or for tissue engineering because they offer several practical advantages. They can be obtained in relatively large numbers through standard clinical procedures, and they are easily expanded in culture. The multi-lineage potential of MSC, in combination with their immunoprivileged status, make MSCs a promising source for cell therapy in cardiac diseases. Here we provide an overview of biological characteristics of MSCs, experimental animal studies and early clinical trials with MSCs. In addition, we discuss the routes of cell delivery, cell tracking experiments and current knowledge of the mechanistic underpinnings of their action.",
keywords = "Acute myocardial infarction, Cell transplantation, Heart failure, Mesenchymal stem cells",
author = "Schuleri, {K. H.} and Boyle, {A. J.} and Joshua Hare",
year = "2007",
month = "12",
day = "1",
doi = "10.1007/978-3-540-68976-8-9",
language = "English",
isbn = "9783540689751",
volume = "180",
series = "Handbook of Experimental Pharmacology",
pages = "195--218",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Mesenchymal stem cells for cardiac regenerative therapy

AU - Schuleri, K. H.

AU - Boyle, A. J.

AU - Hare, Joshua

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Until recently, the concept of treating the injured or failing heart by generating new functional myocardium was considered physiologically impossible. Major scientific strides in the past few years have challenged the concept that the heart is a post-mitotic organ, leading to the hypothesis that cardiac regeneration could be therapeutically achieved. Bone marrow-derived adult stem cells were among the first cell populations that were used to test this hypothesis. Animal studies and early clinical experience support the concept that therapeutically delivered mesenchymal stem cells (MSCs) safely improve heart function after an acute myocardial infarction (MI). MSCs produce a variety of cardio-protective signalling molecules, and have the ability to differentiate into both myocyte and vascular lineages. Additionally, MSCs are attractive as a cellular vehicle for gene delivery, cell transplantation or for tissue engineering because they offer several practical advantages. They can be obtained in relatively large numbers through standard clinical procedures, and they are easily expanded in culture. The multi-lineage potential of MSC, in combination with their immunoprivileged status, make MSCs a promising source for cell therapy in cardiac diseases. Here we provide an overview of biological characteristics of MSCs, experimental animal studies and early clinical trials with MSCs. In addition, we discuss the routes of cell delivery, cell tracking experiments and current knowledge of the mechanistic underpinnings of their action.

AB - Until recently, the concept of treating the injured or failing heart by generating new functional myocardium was considered physiologically impossible. Major scientific strides in the past few years have challenged the concept that the heart is a post-mitotic organ, leading to the hypothesis that cardiac regeneration could be therapeutically achieved. Bone marrow-derived adult stem cells were among the first cell populations that were used to test this hypothesis. Animal studies and early clinical experience support the concept that therapeutically delivered mesenchymal stem cells (MSCs) safely improve heart function after an acute myocardial infarction (MI). MSCs produce a variety of cardio-protective signalling molecules, and have the ability to differentiate into both myocyte and vascular lineages. Additionally, MSCs are attractive as a cellular vehicle for gene delivery, cell transplantation or for tissue engineering because they offer several practical advantages. They can be obtained in relatively large numbers through standard clinical procedures, and they are easily expanded in culture. The multi-lineage potential of MSC, in combination with their immunoprivileged status, make MSCs a promising source for cell therapy in cardiac diseases. Here we provide an overview of biological characteristics of MSCs, experimental animal studies and early clinical trials with MSCs. In addition, we discuss the routes of cell delivery, cell tracking experiments and current knowledge of the mechanistic underpinnings of their action.

KW - Acute myocardial infarction

KW - Cell transplantation

KW - Heart failure

KW - Mesenchymal stem cells

UR - http://www.scopus.com/inward/record.url?scp=34547579296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547579296&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-68976-8-9

DO - 10.1007/978-3-540-68976-8-9

M3 - Chapter

SN - 9783540689751

VL - 180

T3 - Handbook of Experimental Pharmacology

SP - 195

EP - 218

BT - Handbook of Experimental Pharmacology

ER -